

Last updated on 31 May 2021

[Source link](#)

Welcome

After the release of the first issue of VACscene in May, both TIACA and Pharma.Aero received very positive feedback on the joint initiative. The feedback received will also be extremely useful as we further develop and finetune future issues of the VACscene.

Whilst preparing this second issue of VACscene, we already see a significant jump in numbers, underlining the speed in which this pandemic is managed globally. In this issue, some new developments caught our attention. Firstly, we see an increased EU order amount in excess of the total population. This may indicate the need of a booster 3rd shot and the EU's support to provide developing and emerging countries with some of the surplus vaccines. Secondly, we see 3 new vaccines producers on the block accepted for administration to the population, although the number of doses made available at the initial stage might be low. The GSK Sanofi vaccine project is coming to the market, resulting in many signed deals and expanding the global total of signed deals. To expedite and meet the production and delivery schedule, there is a need for higher production capacity of vaccines. US and Belgium have further increased production capacity with additional 600 million vaccines for the year 2021. The dynamic and rapid changing statistics will further drive the supply of these vaccines globally.

Glyn Hughes & Frank Van Gelder

Updates on the Covid-19 vaccine global production

Company name	Vaccine name	Production sites	Approved production	Signed deals	Approved countries	Vaccine type	Doses
AstraZeneca	AZD1222	16	2,1 Billion	1,624 billion	98	Non Replicating Viral Vector	2
BIONTECH Pfizer	BNT162b2	6	3 Billion	3 billion	84	mRNA	2
moderna	mRNA - 1273	5	800 Million	1.3 billion	46	mRNA	2
SINOPHARM	BBIBP-CoV (Beijing)	2	1 Billion	120 million	41	Inactivated	2
МИНИСТЕРСТВО ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ	Sputnik V	6	390 Million	442,4 million	68	Non Replicating Viral Vector	2
CanSinoBIO	Ad5-nCoV	4	500 Million	30,4 million	5	Non Replicating Viral Vector	2
SERUM INSTITUTE OF INDIA PVT. LTD.	Covishield	1	200 Million		33	Non Replicating Viral Vector	2
BHARAT BIOTECH	Covaxin	3	494,2 Million	108,5 million	9	Inactivated	2
janssen	Ad26.COVS.2.S	7	1 Billion	1,15 billion	41	Non Replicating Viral Vector	1
sinovac	Coronavac	4	1,75 Billion	1,25 billion	25	Inactivated	2
ZFSW INSTITUTE OF MEDICAL BIOLOGY CHINESE ACADEMY OF MEDICAL SCIENCES	RBD-Dimer	1	1 Million	0	2	Protein Subunit	2
BEKTOP	EpiVacCorona	1	5 Million	0	2	Protein Subunit	2
БАВРИЙСКИЙ СЕРУМНЫЙ ИНСТИТУТ	KoviVac	1	3 Million	0	1	Inactivated	2
RIBSP	QazCovid-in	1	4 Million	0	1	Inactivated	2
MINHAI 民海生物	SARS-CoV-2 Vaccine (Vero Cells)	1	5 Million	0	1	Inactivated	2

[Source link](#)

Hot from the needle



More flexible storage conditions for BioNTech/Pfizer's COVID-19 vaccine

EMA's human medicines committee (CHMP) has recommended a change to the approved storage conditions of Comirnaty, the COVID-19 vaccine developed by BioNTech and Pfizer, that will facilitate the handling of the vaccine in vaccination centres across the European Union (EU).

This change extends the approved storage period of the unopened thawed vial at 2-8°C (i.e. in a normal fridge after taking out of deep-freeze conditions) from five days to one month (31 days). The change was approved following assessment of additional stability study data submitted to EMA by the marketing authorisation holder. Increased flexibility in the storage and handling of the vaccine is expected to have a significant impact on planning and logistics of vaccine roll-out in EU Member States.

The changes described will be included in the publicly available information on Comirnaty and will be implemented by the marketing authorisation holder in updated product labelling. Users are reminded to always refer to the label and package leaflet of the supplied product for the correct storage information.

EMA is in continuous dialogue with the marketing authorisation holders of COVID-19 vaccines as they seek to make manufacturing improvements to enhance vaccine distribution in the EU.

Takeda Announces Approval of Moderna's COVID-19 Vaccine in Japan

Saturday, May 22, 2021

[Read the full article](#)

Pfizer vaccine authorized for children ages 12-15 by FDA

Tuesday, May 25, 2021

[Read the full article](#)

Moderna's single-dose Covid-19 vaccine in India likely next year

Tuesday, May 25, 2021

[Read the full article](#)

India's Panacea Biotec begins producing Russia's Sputnik V vaccine: RDIF

Monday, May 24, 2021

[Read the full article](#)

WHO approves Sinovac COVID vaccine, the second Chinese-made dose listed

Tuesday, June 1, 2021

[Read the full article](#)

Vaccine clinical trial updates

Protein Subunit					
FINLAY-FR-1 Instituto Finlay de Vacunas Cuba 4 trials in 1 country	Recombinant Protein Sonofi/GSK 4 trials in 2 countries	CIGB-66 Center for Genetic Engineering and Biotechnology (CIGB) 5 trials in 1 country	SCB-2019 Clover 5 trials in 10 countries	COVAXX UB-612 4 trials in 1 country	FINLAY-FR-2 Instituto Finlay de Vacunas Cuba 3 trials in 1 country
Protein Subunit	VLP	DNA			Non Replicating Viral Vector
NVX-CoV2373 Novavax 5 trials in 6 countries	Plant-based VLP Medicago 3 trials in 2 countries	AG0302-COVID19 AnGes 4 trials in 1 country	INO-4800 Inovio 6 trials in 3 countries	ZyCoV-C Zydus Cadila 5 trials in 1 country	GRAd-COV2 ReiThera 5 trials in 12 countries
RNA			Inactivated		
CVnCoV Curevac 5 trials in 4 countries	BNT162b1 Pfizer/BioNTech 5 trials in 3 countries	mRNA Walvax 4 trials in 1 country	Inactivated (Vero Cells) Chinese Academy of Medical Sciences 5 trials in 3 countries	COVID-19 Inactivated Vaccine Shifa Pharmed Industrial Co 4 trials in 1 countries	VLA2001 ValNeva 3 trials in 1 country


Last updated on 25 May 2021

[Source link](#)

Global vaccine administration progress

COVID-19 vaccine doses administered

Total number of vaccination doses administered. This is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses).




Total: 1.59 billion

[Source link](#)

Source: Official data collated by Our World in Data - Last updated 31 May, 10:20 (London time) OurWorldInData.org/coronavirus • CC BY

Share of the population fully vaccinated against COVID-19, May 30, 2021

Share of the total population that have received all doses prescribed by the vaccination protocol. This data is only available for countries which report the breakdown of doses administered by first and second doses.




[Source link](#)

Source: Official data collated by Our World in Data - Last updated 31 May, 10:20 (London time) OurWorldInData.org/coronavirus • CC BY

Number of people fully vaccinated against COVID-19, May 31, 2021


Total number of people who received all doses prescribed by the vaccination protocol. This data is only available for countries which report the breakdown of doses administered by first and second doses.



[Source link](#)

Source: Official data collated by Our World in Data - Last updated 1 June, 10:30 (London time) OurWorldInData.org/coronavirus • CC BY

Production forecast 2021



China 2.613.000.000

Sinovac	1.013.000.000
Sinopharm	1.000.000.000
CanSinoBio	500.000.000
AstraZeneca	100.000.000

India 1.9 billion

AstraZeneca	1.000.000.000
Bharat BioTech	570.000.000
SIOI	200.000.000
GNC	126.000.000

US 2.260.000.000

BioTech Pfizer	1.000.000.000
Moderna	740.000.000
AstraZeneca	420.000.000
Bharat BioTech	100.000.000

Belgium 1.125.000.000

BioTech Pfizer	1.125.000.000
----------------	---------------

Australia 50.000.000

AstraZeneca	50.000.000
-------------	------------

Brazil 265.500.000

AstraZeneca	163.500.000
GNC	56.000.000
Sinovac	46.000.000

Egypt 80.000.000

Sinovac	80.000.000
---------	------------

France 108.000.000

Johnson&Johnson	108.000.000
-----------------	-------------

Germany 796.000.000

BioTech Pfizer	750.000.000
GNC	36.000.000
AstraZeneca	10.000.000

Indonesia 250.000.000

Sinovac	250.000.000
---------	-------------

Italy 25.000.000

Johnson&Johnson	25.000.000
-----------------	------------

Japan 30.000.000

AstraZeneca	30.000.000
-------------	------------

Kazakhstan 5.640.000

GNC	5.640.000
-----	-----------

Malaysia 15.000.000

Sinovac	12.000.000
CanSinoBio	3.000.000

Mexico 285.000.000

AstraZeneca	250.000.000
CanSinoBio	35.000.000

Netherlands 692.000.000

Johnson&Johnson	692.000.000
-----------------	-------------

Pakistan 3.000.000

CanSinoBio	3.000.000
------------	-----------

South Africa 150.000.000

Johnson&Johnson	150.000.000
-----------------	-------------

South Korea 250.000.000

GNC	150.000.000
Moderna	100.000.000

Spain 85.000.000

Moderna	60.000.000
Johnson&Johnson	25.000.000

Switzerland 125.000.000

BioTech Pfizer	125.000.000
----------------	-------------

Thailand 61.000.000

AstraZeneca	61.000.000
-------------	------------

UAE 100.000.000
















Sinopharm	100.000.000
-----------	-------------

UK 700.000.000

AstraZeneca	700.000.000
-------------	-------------

Source link

Supply chain insights

Company name	Vaccine name	Product temperature	Transport temperature
 AstraZeneca	AZD1222	+2C° to +8C°	+2C° to +8C°
 BIONTECH Pfizer	BNT162b2	-70C°	+15C° to +25C°
 moderna™ messenger therapeutics	mRNA - 1273	-20C°	+2C° to +8C°
 SINOPHARM	BBIBP-CorV (Beijing)	+2C° to +8C°	+2C° to +8C°
 МИНИСТЕРСТВО ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ	Sputnik V	+2C° to +8C°	+2C° to +8C°
 CanSinoBIO	Ad5-nCoV	+2C° to +8C°	+2C° to +8C°
 SERUM INSTITUTE OF INDIA PVT. LTD. Cytus Poonawalla Group	Covishield	+2C° to +8C°	+2C° to +8C°
 BHARAT BIOTECH	Covaxin	+2C° to +8C°	+2C° to +8C°
 janssen PHARMACEUTICAL COMPANIES OF Johnson & Johnson	Ad26.COV2.S	-20C°	+2C° to +8C°
 sinovac	Coronavac	+2C° to +8C°	+2C° to +8C°
 ZFSW INSTITUTE OF MEDICAL BIOLOGY CHINESE ACADEMY OF MEDICAL SCIENCES	RBD-Dimer	+2C° to +8C°	+2C° to +8C°
 BEKTOP	EpiVacCorona	+2C° to +8C°	+2C° to +8C°
 БАКАЛПА КОРПОРАЦИЯ	KoviVac	+2C° to +8C°	+2C° to +8C°
 RIBSP Research Institute for Biological Safety Problems	QazCovid-in	+2C° to +8C°	+2C° to +8C°
 MINHAI 民海生物 WWW.BIOTECHNOLGY.CO.,LTD	SARS-CoV-2 Vaccine (Vero Cells)	+2C° to +8C°	+2C° to +8C°

Source link



Advertisement space

Contact details

www.pharma.aero
secgen@pharma.aero

www.tiaca.org
secretariat@tiaca.org

www.4advice.eu
info@4advice.eu

Authors:
4Advice
Pharma.Aero
TIACA

This publication contains general information only and Pharma.Aero and TIACA are not, by means of this publication, rendering accounting, business, financial, investment, legal, tax, or other professional advice or services. This publication is not a substitute for such professional advice or services, nor should it be used as a basis for any decision or action that may affect your business. Before making any decision or taking any action that may affect your business, you should consult a qualified professional advisor. Pharma.Aero and TIACA shall not be responsible for any loss sustained by any person who relies on this publication.



Copyright © 2021 Pharma.Aero and TIACA. All rights reserved